Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Thrombosis
•
Hematology
•
Antiphospholipid Syndrome
•
Pregnancy
•
Hemostasis/Thrombosis
What guides your choice between prophylactic, intermediate, and full therapeutic dosing of enoxaparin in a woman with APLS and prior fetal loss with no hx of thromboembolic disease?
Related Questions
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
For patients with a history of pregnancy loss, do you evaluate for PAI-1 polymorphisms as part of a thrombophilia workup?
Does a positive lupus anticoagulant alone confer high enough risk that warfarin is preferred over DOACs in antiphospholipid syndrome?
How long would you anticoagulate for a catheter associated DVT in pregnancy?
How would you manage recurrent migratory lower extremity thrombophlebitis that occurs despite being on therapeutic apixaban?
How would you manage superficial vein thrombosis that persists on imaging after treatment with full dose anticoagulation?
For patients with newly diagnosed VTE on IV heparin planned for transition to DOAC, would you start at the loading or maintenance DOAC dose?
How would you manage symptomatic superficial vein thrombosis during pregnancy?
How is your experience with point-of-care INR systems for home monitoring of vitamin K antagonists?
Is there a role for DOAC use for patients with unprovoked PE, that have had recent sleeve gastrectomy with duodenal bypass?
